as patients may think? KSSG, St. Gallen, Switzerland

Similar documents
HIV/STDs and Excretion of HIV in Genital Secretions - Implications for sexual transmission. Pietro L. Vernazza, KSSG, St. Gallen, Switzerland

Sexual transmission of HIV: a heterogeneous event

Fertility Desires/Management of Serodiscordant HIV + Couples

Importance of Viral Suppression to Reduce HIV Transmission: Recent Evidence

HIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP

Outline. HIV and Other Sexually Transmitted Infections. Gonorrhea Epidemiology. Epidemiology 11/2/2012

The Synergy between HIV and other STIs

HIV TRANSMISSION AND PREVENTION KENNETH H. MAYER, M.D. BROWN UNIVERSITY/MIRIAM HOSPITAL FENWAY COMMUNITY HEALTH 5/31/07

Dr Yvonne Gilleece Brighton and Sussex University Hospitals NHS Trust

ART for HIV Prevention:

HIV Reproductive Health: Conception Options in the Era of PrEP

Sexually Transmitted Infection Treatment and HIV Prevention

HIV & Condomless Sex - What is the Risk? Why Not? Alan J. Taege, MD Assistant Professor of Medicine Department of Infectious Disease Cleveland Clinic

ART FOR HIV PREVENTION: PANACEA OR PANDORA S BOX? KENNETH H. MAYER, M.D.

(Part 2): Epidemiology and Infectivity

Genital Herpes in the STD Clinic

SEXUAL TRANSMISSION. SEXUAL TRANSMISSION under ART: Biological Considerations

Guidelines on safer conception in fertile HIV infected individuals

CUMULATIVE PERINATAL HIV EXPOSURE, AUSTRALIA. Date

Professor Thomas Quinn Johns Hopkins Center for Global Health, Maryland, USA

PRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS. Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program

A Sex-informed Framework for HIV Prevention. Robert M. Grant, M.D., M.P.H. Betty Jean and Hiro Ogawa Endowed Investigator

So you want to have a baby? Pre-conception counselling for the HIV affected couple. Dr Louise Gilbert 23 November 2011

So you have HIV and you want to have a baby?

Q and A - the PARTNER Study: new results from PARTNER 2

Biomedical Prevention Update Thomas C. Quinn, M.D.

Answers to those burning questions -

Antivirals and Vaccines: What s old and new in HSV-2 treatment

Fertility Therapy for Women & their Partners Affected by HIV. J. Preston Parry, MD, MPH

HIV : Test and Treat?

Fertility Management in HIV. INTEREST Workshop, 16 Dakar May 2013 Vivian Black, Director Clinical Programmes Wits Reproductive Health & HIV Institute

Prevention of Perinatal HIV Transmission

Gonorrhea Cook County Department of Public Health

Report Back from CROI 2010

Effect of antiviral treatment on the shedding of HIV-1 in semen

HIV Clinical Update- HIV prevention

Pre exposure Prophylaxis (PrEP): Stepping Up HIV Prevention

HIV in Women: A Global View of the HIV Epidemic

Pre-exposure Prophylaxis for HIV Prevention

An Analysis of Genital Tract Derived HIV from Heterosexual Transmission Pairs. Debrah Boeras Emory University October 14, 2008

HIV in Women: A Global View of the HIV Epidemic

The Pregnancy Journey...

Female-to-Male Infectivity of HIV-1 among Circumcised and Uncircumcised Kenyan Men

Women and Viral Load. Together, we can change the course of the HIV epidemic one woman at a time.

Non-occupational HIV Post Exposure Prophylaxis (npep)

HIV Prevention. Recent Advances and Implications for the Caribbean

Quantification of HIV in semen: correlation with antiviral treatment and immune status

Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City

PRECONCEPTION COUNSELING

HIV Prevention in US Women

Disclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000.

PrEP and Behavioral Strategies for HIV Prevention. Douglas Krakower, MD January 30, 2014

HPV Transmission. Rachel Winer, PhD, MPH Department of Epidemiology University of Washington

The Global State of HIV/AIDS. Presented By: Siobhan K. Young, MPH PhD Candidate at UNC Chapel Hill

3 rd International Workshop on Women and HIV January 14 th, 2013

o Changes since 1999 policy statement and 2005 update

Sexually Transmitted Infections. Kim Dawson October 2010

Herpes virus co-factors in HIV infection

Pre-Exposure Prophylaxis: The New Frontier of Prophylaxis Against HIV Infection

Presentation Overview

PEP and PREP. Dr David Hawkins Chelsea and Westminster Hospital

Planned Vaccine Trials to Follow-up on RV 144. Merlin Robb, MD Deputy Director for Clinical Research MHRP

All HIV+ Women on Antiretroviral Therapy Should Breastfeed in Both Low and High Resource Settings VOTE NO!!

HPV Epidemiology and Natural History

HIV Lecture. Anucha Apisarnthanarak, MD Division of Infectious Diseases Thammasart University Hospital

Ron Gray, MBBS, MFCM, MSc Johns Hopkins University. STIs in an International Setting

To increase listener s awareness of the reality of discordance

Population attributable fraction of genital inflammation and ulceration in HIV risk among discordant couples, Zambia,

KEY ELEMENTS FOR SUCCESSFUL INTERVENTION (1)

PrEP for Women: HIV Prevention in Family Planning Settings

HIV - Preventing New Infections: New Options, Readjusted Approaches

Contraception & HIV Still searching for answers after >2 decades

Providing Hope in the midst of Despair: A Person Centered Response to the AIDS Epidemic : Ethical Principles Moving Forward

HIV Prevention and Reproductive Choices

Breast-Milk Infectivity in Human Immunodeficiency Virus Type 1 Infected Mothers

Infertility Treatment and HIV

PrEP Integration into Primary Care

ART and Prevention: What do we know?

ART and Transmission. Martin Fisher. Brighton and Sussex University Hospitals, UK

Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention

The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN

5. Over the last ten years, the proportion of HIV-infected persons who are women has: a. Increased b. Decreased c. Remained about the same 1

RESEARCH. Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study

It is a good idea for anyone having sex to get tested regularly and treated for STIs if necessary.

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

Where Epidemiology Meets Biology: Primary HIV Infection and Sexual Transmission

The Latest on HIV Testing. Dominika Seidman, MD MAS

Obstetric Complications in HIV-Infected Women. Jeanne S. Sheffield, MD Maternal-Fetal Medicine UT Southwestern Medical School

Objectives. Outline. Section 1: Interaction between HIV and pregnancy. Effects of HIV on Pregnancy. Section 2: Mother-to-Child-Transmission (MTCT)

PrEP: Pre Exposure Prophylaxis

Treating Infertility

Terapia come prevenzione e ruolo del community viral load (CVR) Andrea Antinori INMI L. Spallanzani IRCCS, Roma

Quantifying sexual exposure to HIV within an HIV-serodiscordant relationship: development of an algorithm

Attendees will be able to:

Biomedical Prevention in HIV

PrEP efficacy the evidence

ZIKA Jordan H. Perlow MD Banner University Medical Center Division of Maternal Fetal Medicine Phoenix Perinatal Asoociates

Module 2: Integration of HIV Rapid Testing in HIV Prevention and Treatment Programs

PrEP in the Real World: Clinical Case Studies

Answering basic questions about HIV

Transcription:

HIV in Semen - Is it as infectious as patients may think? Pietro L Vernazza Pietro L. Vernazza, KSSG, St. Gallen, Switzerland

Heterosexual Transmission HIV-pos. HIV-neg. Clumeck N, et al, NEJM, 1989;321:1460

Is it as infectious as patients may think What do you think? What is your estimate of transmission risk after one single sexual act A) in the absence of treatment B) during fully supressive HAART 100% - 10% - 1% - 1:10 3-1:10 4-1:10 5-1:10 6

PHI Transmission couple 22 y/o woman AUG+ 7.8 14.8 21.8 28.8 4.9 11.9 18.9 25.9 2.10 9.10 24 y/o man log 10 /ml or Ejac. HIV-RNA 6 5 4 3 2 1 Blood plasma Seminal plasma Seminal cells (DNA) HIV-Ag - - ++ C.trach.-PCR - + + AZT+3TC+ABC+APV AZM 7.8 14.8 21.8 28.8 4.9 11.9 18.9 25.9 2.10 9.10

Transmission risk per sex contact Partner studies Anonymous contact 1-9% partner pos. <0.3% per contact 3.1% - 8.2% 9-18% partner pos 0.3% per contact Padian, JAMA 1987 De Vincenzi, NEJM 1994 Mastro, AIDS 1994 Nicolosi, Epidemilogy 1994 Cameron, Lancet 1989

Risk after single sexual exposure 422 customers of Kenyan prostitutes 293 HIV-neg, prospectively followed 12% s/c rate in 12 wk period Non circumcision: OR 8.2 (3-23) GUD OR 4.7 (1.3-17) 73 men: only one single contact 8.2% s/c rate (6/73), 43% of uncircumcised Cameron et al, 1989, Lancet ii:403-7

Mastro study, Thailand 1115 military conscripts (21y) 6.9% HIV-pos (n=77) Sex with female prostitutes mathematical modelling: risk after single contact: 3.1% (2.5-4.0) adjusted for random error in self reported frequency of contact: 5.6% (4.1-7.5%) Risk signif. higher in men reporting Hx of STD Mastro et al, 1994, Lancet 343:204-7

Sexual Transmission of HIV Risk of transmission enhanced with: Low CD4 counts Symptomatic disease High blood viral load Genital inflammation PHI r = 0506 0.5-0.6

VL and HIV-Transmission-Risk i 30 Rakai (Uganda) 453 HIV-disc. couples 11.6 % TR / year % partners infecte ed 20 10 0 <400 400-3500- 10'000- >50000 3500 10'000 50'000 HIV-RNA load (cp/ml) Quinn, NEJM, 2000; 342:921-9.

HIV-Primary Infection HIV-RNA in blood and semen IV-RNA (log 10 cp p/ml) Blood H 8 7 6 5 r = 0.80 P < 0.001 000 4 Group BL - PHI 3 Early PHI 2 Late PHI 1 1 2 3 4 5 6 Seminal plasma HIV-RNA (log 10 cp/ml) Vernazza, 2000, Quest-Study Group

HIV in semen & risk per coital act Chakraborty et al. AIDS 2001,15: 621-7

Primary HIV Infection Marked increase of transmission i risk 0.05 isk ct ssion r xual ac nsmis er sex Tra p 0.04 0.03 0.02 0.01 0.00 0 2 4 6 8 10 12 14 16 18 20 Weeks after infection Pilcher et al JID 2004; 189:1785 92

Brenner et al, JID 2007; 195:951 9 14

Summary 1 HIV in genital tract follows blood VL Transmission risk high during PHI Q: What is the effect of treatment

HIV in semen under HIV therapy >1 log drop <0.5 log drop Vernazza P. et al, AIDS, 1997;11:1249 1254

HIV V-RNA (lo og 10 cp/ml l) Viral load in blood vs. semen during the course of treatment t t in PHI g 10 c/ejac c) HIV- V-DNA (lo 8 RNA blood 7 RNA seminal fluid DNA seminal cells 6 5 4 3 2 1 N=32 N=22 N=22 N=39 Baseline Early Late Acute & Primary HIV Infection CAD

HIV in Semen during HAART patient ts (%) with pos s. n seme n HIV dete ection i 100% 80% 60% 40% 20% 6 Pat.2: Pat.1: D4T+SQV+RTV DDI+D4T+HU 6 5 p<0.0001 4 3 2 semen No Therapy (control) HAART, RNA<400 blood BL Wk 78 n=55 n=114 0% HIV-RNA HIV-DNA Vernazza et al., AIDS, 2000; 14:117-21

HIV in Semen during HAART patient ts (%) with pos s. n seme HIV dete ection i 100% nno Therapy (control) HAART, RNA<400 80% p<0.0001 60% p=0.025 40% 20% n=55 n=114 0% HIV-RNA HIV-DNA Vernazza et al., AIDS, 2000; 14:117-21

Zhu et al. Transmitted HIV in semen Zhu et al, 1996, JVirol

Cell-free vs. Cell-associated trm Long et al, Nat Med, 2000; 6:71-5

HIV diversity develops over time 6 mt time infection

HIV diversity in early infection Men: 1 pattern <5% diversity: homogenous oge ous pattern Women: 2 patterns homogenous pattern heterogenous pattern

Potential hypotheses Infected by different partners Similar # sex acts / wk Similar fraction with single partner Phylogenetic clustering Differences in immune response 5/6 w already heterogenous before s/c Difference in transmitted virus

Hypothesis Sex. Trsm of HIV = rare event 1 hit One single hit could be Free virus HIV-infected cell Multiple strains Cell-associated

HIV-diversity, STDs and DNA 156 female sex workers, Kenya 89 heterogenous, 67 homogenous viral strain Sagar, AIDS, 2004;18:615-9

QUEST: HIV-RNA in semen during tx HIV- RNA (log 10 cp/m ml) Plasma RNA 7 Semen RNA 6 5 4 3 #6991 2 1 0 100 200 300 400 500 Days on Therapy

QUEST: HIV-DNA in semen during tx g 10 /Ejac c.) HIV- -DNA (lo 7 6 5 4 3 2 Plasma RNA Viral DNA / ejaculate #6991 1 0 100 200 300 400 500 Days on Therapy

Malawi urethritis project: HIV-RNA in semen 65 6.5 6 log 10 HIV- V-1 RNA co opies/ml 5.5 5 4.5 4 3.5 3 2.5 BL Wk2 BL Wk1 Wk2 BL Wk1 Wk2 BL Wk1 Wk2 Dermatology Urethritis GC NGU Cohen et al, Lancet 1997; 349:1868-73

HIV-Infectiousness I over time PHI STDs Infectiousness (arbritrary scale) Weeks Months / Years

Urethritis during HAART (n=24) Plasma HIV-RNA Semen HIV-RNA 2 / 20 positive 20 (low level) - + 4 4 / 4 positive (high level) Sadiq et al, AIDS 2002;16:219-25

HAART: Latent t HIV in seminal cells 28 men 60 Supressive HAART 50 PBMC and SC Viral growth 2-LTR-circular DNA itive % pos 70 40 30 20 10 0 Viral Cx PBMC 2-LTR-circ DNA Seminal Cells Nunnari G. et al, AIDS, 2002; 16:39-45

Decline in infectivity* w. HAART HIV incidence in SF-MSM during 1994-1999 Infectivity* 0.12 0.048 * per-partnership probability of trx from HIV+ partner from HIV+ partner - 60% Porco et al, AIDS 2004, 18:81 88

Literature Review Case reports of trsm under HAART

Artificial Insemination in HIV- discordant d couples(kssg) Experiences until 24.6.04 Couples counselled 72 Inseminations started 43 (60%) Total Inseminations 145 Insem/couple: Median 3 (1-16) Pregnancies 17 12% of all Cycles 40% of all couples

HIV und Kinderwunsch Retrospective analysis Semprini: 500 couples contacted t after counselling Half of couples had conceived natrually 1 woman was HIV-infected Is our intervention missing it s target? Vernazza et al, AIDS 28.2.06, S. 635-6

HIV-discordant couples in Insemination Program HIV-RNA in semen Are we reducing a zero Risk? 68 Chakraborty et al. AIDS 2001,15: 621-7

HAART und Transmissionsrisiko Biologische Daten: Risiko reduziert HAART: Ø Transmission dokumentiert Epid. Studien Fallserien z.b. Barroso, JAIDS 2006 38

License to Love Counselling of HIV-d/c couples 1. Information of both partner about transmission risks 2. Rule out asymptomatic STDs 3. Maintain i fully suppressive HAART 4. Timing of unprotected intercourse (LH-urine test) 5. HIV-Pre-Exposure Prophylaxis (TDF)

License to Love Pregnancy-rates rates in first 21 couples 100% 25 80% Couples Preg.Rate 20 Pregna ancy Rate (c cumm.) 60% 40% 20% 15 10 5 Num mber of cou uples 0% 0 1 3 5 7 9 >10 Number of Cycles